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Trends in the incidence of treated end-stage renal failure in The
Netherlands: Hope for the future? This study shows that in The
Netherlands there is a changing pattern in incidence of renal
replacement therapy over time when adjusted for age and sex.
There has been an almost linear increase in crude incidence
rates during four decades. However, unlike the situation else-
where in the Western world, a flattening of the curve has been
observed during the last six years. The growing incidence of
end-stage renal disease (ESRD) due to especially hypertensive
renovascular disease and diabetes mellitus type 2 has been neu-
tralized by a decrease in ESRD due to glomerulonephritis, uro-
logic interstitial nephritis, and diabetes mellitus type 1. The lat-
ter observations suggest that renoprotective interventions can
be successful on a population level, and thus, provide hope for
the future. To battle the increase in ESRD due to atherosclerosis
and diabetes mellitus type 2–related renal disease, it is impor-
tant that screening programs are being developed that enable us
to identify in an early phase patients at risk for development of
ESRD who may benefit from preventive strategies. Population
screening for albuminuria will be helpful in this respect.
Randomized controlled studies have proven in the last
decade that several therapeutic strategies may preserve
renal function in patients with diabetic, as well as non-
diabetic renal disease. These therapeutic strategies in-
clude dietary protein restriction, strict blood pressure
control, cholesterol lowering, angiotensin-converting en-
zyme (ACE) inhibition, and angiotensin II (Ang II) an-
tagonism [1–7]. In general, it has been shown that patients
with higher levels of albuminuria/proteinuria especially
may benefit from these interventions [2, 7, 8]. These pos-
itive findings have led to active case finding in general
practice by family care physicians, internists, endocrinol-
ogists, and nephrologists. Individuals at risk, such as di-
abetics, are screened for renal function abnormalities,
albuminuria or proteinuria. If present, renoprotective in-
tervention is started.
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Despite these positive findings in clinical trials, it is
disappointing to notice that in the Western world the in-
cidence of end-stage renal disease (ESRD), for which
renal replacement therapy (RRT) is started, continues to
increase. This trend is observed in the United States [9,
10], Japan [11], Australia [12], and Europe [13]. The cause
of this gradual increase in the need for RRT is manifold,
among others due to aging. However, the year on year
increase in incidence of RRT also seriously questions the
efficacy of renoprotective interventions. It could well be
that these interventions in a nontrial setting are not effi-
cacious, or do not preclude, but only postpone, the need
for RRT.
Interesting in this regard is a recent report by the
ERA—EDTA Registry Committee (European Renal
Association–European Dialysis and Transplantation As-
sociation). The report showed that in Europe, from the
nine countries under study, only in The Netherlands had
the need for RRT flattened out from 1996 through 1999
[13]. We questioned whether this observation was merely
a temporary event, and if not, what may be the cause. We
therefore studied the RRT incidence in The Netherlands,
analyzing two age groups and various renal diagnoses.
METHODS
Population
The data for this study come from RENINE, the
national registry for renal replacement therapy in The
Netherlands [14]. This registry collects data from dialysis
and transplantation centers in The Netherlands on all pa-
tients with ESRD planned for chronic RRT. New patients
(regardless of whether initial therapy was hemodialysis,
peritoneal dialysis, or transplantation) were identified be-
tween the start of the chronic RRT program in January
1, 1964 and December 31, 2002. From 1964 through 1986
data collection by RENINE have been retrospective, us-
ing data from yearly surveys, EDTA, and Eurotransplant
databases. Random tests using these surveys showed a
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Table 1. Incidence of ESRD treated with renal replacement therapy in The Netherlands according to the ERA-EDTA renal diagnoses
Incidence of treated ESRD pmp
Crude incidence Adjusted incidence
Subgroups ERA-EDTA codes 1970 1980 1990 2002 1970 1980 1990 2002
Unknown 00 0.0 2.5 6.5 14.7 0.0 2.4 5.6 11.1
Glomerulonephritis/-pathy 10–19 7.0 9.7 11.6 10.0 7.0 9.2 10.1 8.3
Interstitial nephritis
Urologic 20–25 2.2 6.2 6.9 4.3 2.2 6.0 6.3 3.5
Nonurologic (toxic) 29–39 0.5 3.5 2.8 3.7 0.5 3.5 2.5 2.7
Cystic kidney disease 40–49 1.0 4.1 6.5 7.1 1.0 4.0 6.0 5.5
Other congenital/hereditary kidney disease 50–66 0.6 1.1 0.9 1.9 0.6 1.0 1.0 1.8
Renal vascular disease 70, 71, 72, 79 0.3 2.8 11.4 21.7 0.3 2.7 10.0 16.3
Diabetes mellitus 1 80 0.0 0.4 6.7 5.1 0.0 0.4 5.9 4.1
Diabetes mellitus 2 81 0.0 1.3 2.5 12.1 0.0 1.3 2.2 9.4
Other multisystem diseases 73, 74, 83–89 0.1 2.5 5.0 7.5 0.1 2.4 4.4 6.1
Miscellaneous 90–99 0.6 1.5 3.1 5.3 0.6 1.4 2.8 4.4
Total 13.3 36.3 66.0 96.6 13.4 35.1 58.8 75.8
Data are given as crude incidence rates and as incidence rates adjusted for age and sex distribution of the 1964 population (per million people). Detailed classification
of renal diseases and ERA-EDTA codes appear in [20].
correspondence with the RENINE database of at least
97%. From 1986 onward data were collected prospec-
tively, with a 100% response rate by the dialysis and trans-
plantation centers.
Analysis
Incidence rates were studied per year from 1964 to
2002. Data were provided as crude incidence rates and
incidence rates adjusted for age (in five-year classes) and
sex, with the mid-1964 Dutch population as the refer-
ence population [15]. Incidence rates were expressed as
the number of patients per million people (pmp). Mid-
year census population estimates by age and sex were de-
rived from the Central Bureau for Statistics (CBS) in The
Netherlands. For graphical depiction, incidence rates per
year were calculated as the sliding mean of a three-year
period to obtain more gradual curves (e.g., for 1978, the
average incidence rate of 1977/1979 is adopted). For anal-
yses, patients entering the RRT program were subdivided
according to age (using a cut-off value of 60 years) and
according to renal diagnoses (using ERA-EDTA codes;
Table 1).
RESULTS
The RRT program in The Netherlands started in 1964
when four patients with ESRD were treated with chronic
hemodialysis. At that moment the population of The
Netherlands consisted of 12,056,000 people (10,406,000
aged <60 and 1,650,000 ≥60 years). In 2002, the pop-
ulation had grown to 16,149,000 (13,176,000 aged <60
and 2,973,000 ≥60 years). In that year, 1560 patients
started chronic RRT, representing a crude incidence of
96.6 pmp. When adjusted for the age and sex distribu-
tion of the 1964 population, this number is 75.8 pmp.
Table 1 shows the crude and adjusted incidence data of
ESRD treated with RRT according to the various renal
diagnoses (ERA-EDTA codes). In the first two decades,
ESRD due to glomerulonephritis and interstitial nephri-
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Fig. 1. Patients starting renal replacement therapy. (A) shows crude
incidence data, whereas (B) shows incidence data corrected for age and
sex (expressed as per million people, pmp).
tis were the most common causes for starting RRT. For
instance, in 1980 the adjusted incidence rate of RRT for
these diagnoses, when expressed as percentage of the
total adjusted incidence rate, was 26.2% and 17.1%, re-
spectively. In the last decade, the incidence of treated end-
stage renal failure (ESRF) due to these renal diagnoses
has fallen, both absolute (Table 1), as well as relative. In
2002, the relative contribution of glomerulonephritis and
urologic interstitial nephritis to the total adjusted inci-
dence of RRT had decreased to 10.9% and 4.6%, respec-
tively. At the moment, the predominant causes are renal
vascular disease, diabetes mellitus type 2, and cause “un-
known” (expressed as percentage of the total adjusted
incidence rate 21.5%, 12.4%, and 14.6%, respectively).
Figure 1 shows that the crude incidence of RRT in The
Netherlands has grown steadily over the years, both in
the young and in the elderly. However, when adjusted
for age and sex, it appears that the incidence of RRT has
stabilized from 1996 onward for the total population. This
is due to a flattening of the curve from 1988 onward for
people less than 60 years of age, but also the curve for
those over 60 tends to flatten.
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Fig. 2. Patients younger than 60 years of age starting renal replacement
therapy, subdivided according to the most common renal diagnoses. (A)
Data for diabetes mellitus type 2 (ERA-EDTA code 81; DM 2), renal
vascular disease (70/79; excluding 73, 74; RVD), and the group unknown
(00) are shown. (B) Data for glomerulonephritis (10/19; GN), interstitial
nephritis (20/29; IN), and diabetes mellitus type 1 (80; DM 1) are shown.
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Fig. 3. Patients older than 60 years of age starting renal replacement
therapy, subdivided according to the most common renal diagnoses.
(A) Data for diabetes mellitus type 2 (ERA-EDTA code 81; DM 2),
renal vascular disease (70/79; excluding 73, 74; RVD), and the group
unknown (00) are shown. (B) Data for glomerulonephritis (10/19; GN),
interstitial nephritis (20/29; IN), and diabetes mellitus type 1 (80; DM
1) are shown.
When the two age groups are subdivided according to
renal diagnoses, it shows that in people less than 60 years
of age the adjusted incidence of RRT for ESRD due to
renal vascular disease, diabetes mellitus 2, and the ERA-
EDTA code “unknown” increases over time (Fig. 2). At
the same time the adjusted incidence of RRT for ESRD
due to glomerulonephritis, interstitial nephritis due to
urologic causes, and diabetes mellitus type 1 decreases
(Fig. 2). Similar trends are observed in the people over
60 years of age (Fig. 3). However, the increases in ad-
justed incidence of RRT for ESRD due to renal vascular
disease, diabetes mellitus 2, and the ERA-EDTA code
“unknown” in this specific age group is far steeper. The
percentage of new ESRD cases due to renal vascular dis-
ease, diabetes mellitus type 2, and unknown is at present
60% for those over 60, but also already 33% in those less
than 60 years of age. When men and women are analyzed
separately, similar trends are observed.
The annual adjusted incidence rates for age and sex for
most other renal diagnoses (e.g., toxic tubulopathy, cys-
tic kidney disease, and other congenital/hereditary renal
diseases) have remained approximately stable over the
last 20 years (Table 1).
DISCUSSION
This study shows that in The Netherlands there is a
changing pattern in incidence of RRT over time when
adjusted for age and sex. There has been an almost linear
increase during four decades. The last six years, however,
a flattening of the curve has been observed. The grow-
ing incidence of ESRD due to hypertensive renovascular
disease and diabetes mellitus type 2 is neutralized by a
decrease in ESRD due to glomerulonephritis, urologic
interstitial nephritis, and diabetes mellitus type 1.
In almost the entire Western world the incidence of
RRT for ESRD is growing [9–13]. Various reasons have
been mentioned to explain this phenomenon. Aging of
the population is one of them. Other reasons are im-
proved accessibility to RRT, increased acceptance for
RRT of frail elderly and physically less healthy, improve-
ment in survival from cardiovascular disease, and others
[9, 16, 17]. These reasons may indeed explain in part the
increase in the need for RRT for diabetic nephropathy
and atherosclerosis-related renal disease. In general, one
would expect such a trend to happen, especially in the
elderly. The observation that the growth in incidence of
RRT for ESRD due to these diseases also takes place
in those aged less than 60 years suggests that even the
overall incidence of these diseases may increase. Indeed,
it has been shown in several reports that the incidence
of diabetes mellitus type 2 and its related comorbidity
increases significantly, even in the relatively young [16,
18].
Like elsewhere in the Western world, the crude in-
cidence of RRT for ESRD increases over time in The
Netherlands. However, when adjusted for age and sex,
it appears that the last six years a flattening of the curve
has occurred (Fig. 1). Thus, the growth in the crude inci-
dence of RRT for ESRD in this latter period is entirely
due to the aging of the population. Stengel et al, studying
data from nine European countries from 1990 through
1999, already noticed this trend in The Netherlands [13].
At the moment this trend had not been observed in any
other country. Our study, extending the observation pe-
riod through 2002, indicates that this is not a temporary
phenomenon, and now continues over a six-year period.
Furthermore promising is that this trend at the moment
appears to take place also in other regions in Europe
(K. Jager, ERA-EDTA Registry Committee, personal
communication).
Given the expected rise in need for RRT due to im-
proved accessibility of RRT and the acceptance of pa-
tients physically less healthy for RRT, it is surprising to
notice that there is in fact a decrease in the age- and sex-
adjusted need for RRT due to glomerulonephritis, uro-
logic interstitial nephritis, and diabetes mellitus type 1. It
is generally assumed that the incidence of the underlying
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diseases is not decreasing. In diabetes mellitus type 1, for
instance, no population has been identified yet in which
the incidence has fallen [19]. These data combined sug-
gest strongly that interventions to prevent ESRD in these
specific disease states are successful on a population level.
Because both in the young, as well as in the elderly, the
need for RRT because of ESRD due to these diseases
decreases, such measures apparently not only postpone
but preclude the need for RRT. To our knowledge, this is
the first study to suggest such a development.
Of course, it is difficult to draw firm conclusions on
observational data from epidemiologic research. Sev-
eral opposing mechanisms may work at the same time,
obscuring the specific effect of separate ones. Misclassi-
fication of renal diagnoses may pose another problem,
especially in the absence of a confirmatory renal biopsy.
For instance, the growth of the absolute and relative con-
tribution to the total incidence of RRT of the group
categorized “cause unknown” may be due to growing
misclassification of other specific renal diagnoses. How-
ever, it is generally agreed that this group represents es-
pecially atherosclerosis-related ESRD. Similar growth of
the group categorized “cause unknown” has moreover
been observed in other countries [9–13]. Thus, it is not
likely that misclassification may explain the decrease in
incidence of treated ESRF due to glomerulonephritis and
urologic interstitial nephritis. Furthermore, the distinc-
tion of diabetes mellitus type 1 and diabetes mellitus type
2 may have led to flaws. Because the rise in incidence of
ESRD due to diabetes mellitus type 2 would have been
expected to result in overclassification of ESRD due to
diabetes mellitus type 1, while in fact a decrease in the
latter has been observed in our study during the last few
years, we don’t think that this poses an important prob-
lem either. Furthermore, a similar decrease in ESRD due
to diabetes mellitus type 1 has recently been observed
in other countries also (U.S. Renal Data System, 2003).
However, keeping the aforementioned in mind, our in-
terpretation of data should be read with caution.
CONCLUSION
The increase in the crude incidence of RRT for ESRD
due to diabetes mellitus type 2 and atherosclerosis-
related renal disease poses an important health care prob-
lem. The concomitant decrease in age- and sex-adjusted
incidence or RRT for ESRD due to glomerulonephritis,
urologic interstitial nephritis, and diabetes mellitus type 2
suggests, however, that renoprotective interventions can
be successful on a population level. These latter data thus
provide hope for the future. Screening programs have to
be developed to identify in an early phase patients with
atherosclerosis and diabetes mellitus type 2 at risk for
development of ESRD, and who may benefit from pre-
ventive strategies. Population screening for albuminuria
may be helpful in this respect.
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